# The association between new and established cardiovascular serum markers

Submission date	Recruitment status	Prospectively registered
19/12/2005	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
19/12/2005	Completed	Results
Last Edited	Condition category	Individual participant data
05/11/2008	Circulatory System	Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

## Type(s)

Scientific

#### Contact name

Dr M. Lobbes

#### Contact details

University Hospital of Maastricht Department of Radiology P.O. Box 5800 Maastricht Netherlands 6202 AZ +31 (0)43 3874910 mlob@rdia.azm.nl

## Additional identifiers

Protocol serial number

**NTR376** 

# Study information

#### Scientific Title

The association between new and established serum markers in cardiovascular disease

#### **Study objectives**

We hypothesise that our newly discovered serum risk markers are positively associated with the presence of cardiovascular diseases.

## Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Received from the local medical ethics committee

## Study design

Randomised, single-blind, active controlled, parallel group trial

#### Primary study design

Interventional

## Study type(s)

Diagnostic

#### Health condition(s) or problem(s) studied

Cardiovascular disease

#### **Interventions**

In the groups AMI, SAP, UAP and controls, the marker concentrations of several potential new risk markers for cardiovascular diseases will be evaluated at inclusion, after 6 months, and after 12 months.

## Intervention Type

Other

#### Phase

**Not Specified** 

#### Primary outcome(s)

(Recurrent) cardiovascular disease e.g. myocardial infarction (MI), SAP, UAP, mortality

## Key secondary outcome(s))

No secondary outcome measures

## Completion date

01/05/2007

# Eligibility

## Key inclusion criteria

Groups of acute myocardial infarction (AMI), stable angina pectoris (SAP), unstable angina pectoris (UAP) and controls will be formed (n = 120). All participants will donate a venous blood sample at inclusion, and after 6 and 12 months. Marker concentration will be evaluated in these blood samples.

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

#### Key exclusion criteria

- 1. Unable to give informed consent
- 2. Cardiovascular disease (CVD) less than 6 months
- 3. Auto-immune diseases
- 4. Malignancies
- 5. Renal insufficiency (less than 40 ml/min creatinine clearance)

#### Date of first enrolment

01/11/2004

#### Date of final enrolment

01/05/2007

## Locations

#### Countries of recruitment

Netherlands

## Study participating centre University Hospital of Maastricht

Maastricht Netherlands 6202 AZ

## **Sponsor information**

## Organisation

University Hospital Maastricht (AZM) (The Netherlands)

#### **ROR**

https://ror.org/02d9ce178

# Funder(s)

## Funder type

Research organisation

#### Funder Name

Netherlands Heart Foundation (Nederlandse Hartstichting) (The Netherlands)

# **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration